Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 9:33 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1729–1752 of 22,466 matching trials from the live ClinicalTrials.gov search.
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Osteopathic Manipulative Treatment (OMT), sham omt
Procedure · Other
Lead sponsor
Michigan State University
Other
Eligibility
49 Years to 80 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Lansing, Michigan
Conditions
Mitochondrial Myopathies, Mitochondrial DNA Mutation, Mitochondrial Diseases, Chronic Progressive External Ophthalmoplegia With Myopathy, Kearns-Sayre Syndrome
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
15 Years to 80 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Atrial Fibrillation
Interventions
Zio XT® Patch
Device
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
65 Years and older
Enrollment
24,060 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2027 – 2033
U.S. locations
1
States / cities
Palo Alto, California
Recruiting No phase listed Observational Accepts healthy volunteers

Biobank for Cholestatic Liver Diseases.

NCT03445585
Conditions
Primary Sclerosing Cholangitis, Primary Biliary Cirrhosis, Cholangiocarcinoma, Liver Cancer
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 85 Years
Enrollment
9,150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2050
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Infection, Surgical Site
Interventions
Intraosseous Vancomycin Injection, Intravenous Vancomycin
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
19 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Houston, Texas
Conditions
Atrial Fibrillation Paroxysmal
Interventions
Farapulse PFA, Pulmonary Vein Isolation alone, Farapulse PFA, Pulmonary Vein Isolation and Left atrial Posterior Wall Isolation
Device
Lead sponsor
Jorge Romero
Other
Eligibility
21 Years to 90 Years
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
18
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Jacksonville, Florida + 13 more
Completed No phase listed Observational Accepts healthy volunteers

Evaluation of a New MR Pulse Sequence to Quantify Liver Iron Concentration

NCT00587535
Conditions
Hemochromatosis
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2011
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Chronic Hepatitis C Virus
Interventions
SIMpill device
Device
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Chicago, Illinois
Active, not recruiting No phase listed Observational

Methadone Perception Survey Study

NCT07537608
Conditions
Pain, Postoperative
Interventions
Survey
Other
Lead sponsor
Ashley Smith
Other
Eligibility
Not listed
Enrollment
199 participants
Timeline
2026 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Terminated Phase 1Phase 2 Interventional Results available

MDX-010 in Treating Patients With Recurrent or Refractory Lymphoma

NCT00089076
Conditions
Adult Grade III Lymphomatoid Granulomatosis, B-cell Chronic Lymphocytic Leukemia, Cutaneous B-cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Intraocular Lymphoma, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Refractory Hairy Cell Leukemia, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, Testicular Lymphoma, Waldenström Macroglobulinemia
Interventions
ipilimumab, laboratory biomarker analysis
Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Chronic Granulomatous Disease, Communicable Disease
Interventions
Gene Therapy Method for CGD, Isolex 300i Magnetic Cell Selector
Drug · Device
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
5 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Recruiting No phase listed Observational Accepts healthy volunteers

Inherited Retinal Degenerative Disease Registry

NCT02435940
Conditions
Eye Diseases Hereditary, Retinal Disease, Achromatopsia, Bardet-Biedl Syndrome, Bassen-Kornzweig Syndrome, Batten Disease, Best Disease, Choroidal Dystrophy, Choroideremia, Cone Dystrophy, Cone-Rod Dystrophy, Congenital Stationary Night Blindness, Enhanced S-Cone Syndrome, Fundus Albipunctatus, Goldmann-Favre Syndrome, Gyrate Atrophy, Juvenile Macular Degeneration, Kearns-Sayre Syndrome, Leber Congenital Amaurosis, Refsum Syndrome, Retinitis Pigmentosa, Retinitis Punctata Albescens, Retinoschisis, Rod-Cone Dystrophy, Rod Dystrophy, Rod Monochromacy, Stargardt Disease, Usher Syndrome
Interventions
Not listed
Lead sponsor
Foundation Fighting Blindness
Other
Eligibility
Not listed
Enrollment
20,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2037
U.S. locations
1
States / cities
Columbia, Maryland
Conditions
Myocardial Infarction, Arrhythmia, Ventricular, Ischemic Cardiomyopathy
Interventions
T Wave Alternans Test
Procedure
Lead sponsor
Medtronic Cardiac Rhythm and Heart Failure
Industry
Eligibility
Not listed
Enrollment
656 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
47
States / cities
Mobile, Alabama • Phoenix, Arizona • Walnut Creek, California + 44 more
Conditions
Musculoskeletal Status, Muscle Weakness
Interventions
Not listed
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
20 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Madison, Wisconsin
Conditions
Melanoma
Interventions
WDVAX
Biological
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2025
U.S. locations
2
States / cities
Boston, Massachusetts
Completed Not applicable Interventional Accepts healthy volunteers

Re-enforcing Safe Sleep Practices for Caregivers With Tangible Incentives

NCT02010450
Conditions
Safe Sleep Education
Interventions
Wearable Blanket (Sleep Sack), Incentive Item
Other
Lead sponsor
University of Kansas
Other
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Wichita, Kansas
Conditions
Critical Limb Ischemia
Interventions
ASCT01 (Autologous Stem Cell Transplantation)
Biological
Lead sponsor
Lifecells, LLC.
Industry
Eligibility
18 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
North Kansas City, Missouri
Conditions
Medulloblastoma Recurrent, Ependymoma Recurrent, ATRT Recurrent, Rare CNS Tumor Recurrent
Interventions
Bevacizumab, Thalidomide, Celecoxib, Fenofibric acid, Etoposide, Cyclophosphamide, Cytarabine, Temozolomide (TMZ), Irinotecan
Drug
Lead sponsor
Medical University of Vienna
Other
Eligibility
Up to 19 Years
Enrollment
232 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2030
U.S. locations
4
States / cities
Chicago, Illinois • Boston, Massachusetts • Grand Rapids, Michigan + 1 more
Not listed Not applicable Interventional Accepts healthy volunteers

Mental Stress & Diesel Exhaust on Cardiovascular Health

NCT03467997
Conditions
Blood Pressure, Inflammation, Catecholamines
Interventions
Trier social stress test, Diesel exhaust
Behavioral · Other
Lead sponsor
University of Washington
Other
Eligibility
22 Years to 49 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Overdose
Interventions
Not listed
Lead sponsor
Hennepin Healthcare Research Institute
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Minneapolis, Minnesota
Completed Not applicable Interventional

Phosphate Kinetic Modeling

NCT01003223
Conditions
End Stage Renal Disease, Hyperphosphatemia
Interventions
Computer algorithm management of hyperphosphatemia
Other
Lead sponsor
Fresenius Medical Care North America
Industry
Eligibility
18 Years and older
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Waltham, Massachusetts
Conditions
Smith-Magenis Syndrome (SMS)
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
1 Month to 115 Years
Enrollment
593 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Pelvic Organ Prolapse, Inflammatory Response, Dysbiosis
Interventions
BiopHreshTM vaginal probiotic supplement (Good Clean Love, Inc. Eugene, OR) and RestoreTM gel., Standard Care
Other
Lead sponsor
Hartford Hospital
Other
Eligibility
18 Years to 89 Years · Female only
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Hartford, Connecticut
Conditions
Toileting Disability, Functional Urinary Incontinence
Interventions
Defeating Urinary Incontinence with Exercise Training
Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
60 Years and older · Female only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Minneapolis, Minnesota